Status:
COMPLETED
Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA
Lead Sponsor:
Cairo University
Conditions:
Diabetic Macular Edema
Ischemic Maculopathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Anti-vascular endothelial growth factor (VEGF) drugs are the mainstay of therapy for diabetic macular edema (DME), substantially improving visual acuity for many diabetics worldwide, and proving effec...
Detailed Description
This is a prospective interventional study to evaluate the effect of repeated intravitreal injections of Anti-VEGF on macular perfusion in diabetic patients using optical coherence tomography angiogra...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old
- Type 1 or 2 diabetes mellitus
- Decreased BCVA due to diabetic macular edema
- Center involvement by the edema on spectral domain optical coherence tomography (SD OCT)
- Any stage of diabetic retinopathy
Exclusion
- Ocular conditions that may affect macular perfusion (e.g. retinal vascular diseases, uveitis, vasculitis etc.)
- History of vitreoretinal surgeries (excluding intravitreal injections)
- Any previous treatment for diabetic macular edema
- Presence of epiretinal membrane involving the macula or vitreomacular traction
- Media opacity preventing good image quality
- Uncontrolled glaucoma
- Thromboembolic events within 6 months
Key Trial Info
Start Date :
October 23 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 24 2018
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT03246152
Start Date
October 23 2017
End Date
December 24 2018
Last Update
January 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University Faculty of Medicine
Cairo, Egypt